Accelerated iTBS for Post Partum Depression

This is an open-label study designed to investigate the feasibility and tolerability of a
novel TMS treatment protocol to treat depression in women with post-partum depression. It is
known that TMS can effectively treat depression. The FDA approved protocol lasts 6 weeks and
is not feasible for many women with post-partum depression. The investigators are
investigating a 3 day treatment for depression which may be more acceptable for this
population. The investigators further hope to characterize the ant-depressant effect of this
protocol in order to design a larger trial.

Inclusion Criteria:

1. Participants must be able to provide informed consent and function at an intellectual
level sufficient to allow accurate completion of all assessment instruments.

2. Participants must be over the age of 18.

3. Participants must meet criteria for post-partum depression: a) onset of symptoms in
the first four weeks postpartum OR b) depressive symptoms starting in the third
trimester and worsening postpartum.

4. Participants must have a HRSD17 >13 at baseline.

Exclusion Criteria:

1. Participants must not be pregnant.

2. Participants must not meet moderate or severe use disorder of any substance with the
exception of Tobacco Use Disorder.

3. Participants must not have current psychotic symptoms.

4. Participants must not have a history of dementia or other cognitive impairment.

5. Participants must not have active suicidal ideation requiring hospitalization or a
suicide attempt within the past 3 months.

6. Participants must not have any contraindications to receiving rTMS (e.g. metal
implanted above the neck, history of seizure, any known brain lesion).

7. Participants must not have any unstable general medical conditions.

8. Participants must not have had pre-eclampsia or eclampsia during pregnancy.